Kymera Therapeutics, Inc. KYMR has announced that partner Sanofi SNY will not advance the development of lead IRAK4 degrader KT-474. This setback was somewhat offset by KYMR’s announcement of an ...

Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers hope. Click for my GILD and KYMR update.

Kymera achieved a $20 million milestone related to preclinical activities of KT-485, reflecting strong progress in its partnership with Sanofi. Kymera could receive up to $975 million in potential ...

Sanofi to advance Kymera’s next-generation oral IRAK4 degrader development candidate, KT-485, into clinical testing and will not advance KT-474 In preclinical testing, KT-485 demonstrated ...

Kymera on Wednesday said Sanofi won't advance KT-474, which in late 2023 entered Phase 2 studies trials in patients with the inflammatory skin diseases hidradenitis suppurativa and atopic dermatitis.

Kymera’s partnerships with Sanofi and Gilead drive value. Piper makes Meta its top large-cap pick, lifts price view on AI-driven ad gains. BofA cuts Molson Coors rating as U.S. beer slide deepens.

Sanofi has decided not to advance KT-474, an earlier IRAK4 degrader candidate. With Kymera’s next earnings report scheduled for August 1, 2025, investors following this development can access ...

Kymera signs $750 million CDK2 drug deal with Gilead and earns $20 million from Sanofi as KT-485 advances toward clinical trials in inflammatory diseases.

Kymera Therapeutics may have signed a $750 million deal with Gilead, but the Watertown biotech also suffered a setback in its partnership with Sanofi.

Sanofi, which is collaborating with Kymera on the development of IRAK4 degraders outside of the oncology and immuno-oncology fields, is progressing the IRAK4 program through clinical development.